What Analysts Are Saying About DermTech Stock

DermTech (NASDAQ:DMTK) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below provides a concise overview of recent ratings by

BenzingaApr 20 01:01

Lake Street Downgrades DermTech to Hold, Announces $0.63 Price Target

Lake Street analyst Thomas Flaten downgrades DermTech from Buy to Hold and announces $0.63 price target.

Analyst UpgradesApr 20 00:01

DermTech Price Target Maintained With a $1.50/Share by Stephens & Co.

DermTech Price Target Maintained With a $1.50/Share by Stephens & Co.

Dow JonesApr 19 22:47

Stephens & Co. : The DermTech (DMTK.US) rating was reaffirmed and adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, with a target price of $1.50.

Stephens & Co. : The DermTech (DMTK.US) rating was reaffirmed and adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, with a target price of $1.50.

Zhitong FinanceApr 19 22:40

Stephens & Co. Reiterates Equal-Weight on DermTech, Maintains $1.5 Price Target

Stephens & Co. analyst Mason Carrico reiterates DermTech (NASDAQ:DMTK) with a Equal-Weight and maintains $1.5 price target.

BenzingaApr 19 22:36

DermTech Cut to Neutral From Buy by BTIG

DermTech Cut to Neutral From Buy by BTIG

Dow JonesApr 19 18:45